EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

A case report on the long‐term use of teduglutide in a pediatric patient with short bowel syndrome

Tsuyoshi Sakurai iD, Hironori Kudo iD, Nakamura Megumi, Ryo Ando, Takuro Kazama, Ryuji Okubo, Masatoshi Hashimoto, Ko Minoshima, Motoshi Wada

Nutrition in Clinical Practice · 2025

DOI: 10.1002/ncp.70023 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Nutrition in Clinical Practice, 2025. Verfasst von Tsuyoshi Sakurai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Tohoku University Hospital, Sendai, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Agents, Peptides, Short Bowel Syndrome. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Short bowel syndrome (SBS) is the leading cause of intestinal failure, frequently necessitating long‐term parenteral nutrition (PN). Teduglutide (TED), a glucagon‐like peptide‐2 analog, has demonstrated efficacy in reducing PN dependence in both adults and children. However, long‐term data in pediatric populations remain limited. We present a case of a male child with SBS who underwent extensive small bowel resection at 5 days of age, resulting in a residual small bowel length of 9 cm, with the total colon and ileocecal valve preserved. Despite home PN and multiple interventions, including management of catheter‐related infections and intestinal complications, PN dependence persisted. At the age of 5 years, the patient was enrolled in a TED clinical trial and continued treatment after its commercial approval. During >6 years of TED therapy, gradual and sustained reductions in PN volume and caloric intake were achieved, ultimately resulting in complete weaning from PN. Growth and nutrition status remained stable, and no severe TED‐related adverse events were reported. This is the first known case documenting TED use for >6 years in a pediatric patient with SBS. Although the response was slower than in previously reported cases, long‐term TED administration led to favorable outcomes, including PN independence. This case underscores the potential for TED to support intestinal adaptation over extended periods and highlights the importance of individualized, long‐term treatment strategies in managing severe pediatric SBS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal AgentsPeptidesShort Bowel SyndromeChild, PreschoolHumansMaleIntestinal FailureIntestine, SmallParenteral NutritionTreatment OutcomeChild

Stichwörter der Autor:innen

intestinal adaptationintestinal failurenutrition weaningparenteral nutritionpediatric short bowel syndrometeduglutide

Substanzen

Gastrointestinal AgentsPeptidesteduglutide

Autor:innen und Institutionen

  • Department of Pediatric Surgery, Tohoku University Hospital, Sendai, Japan.

ORCID-Profile: Tsuyoshi Sakurai, Hironori Kudo

Zitieren

APA

Sakurai, T., Kudo, H., Megumi, N., Ando, R., Kazama, T., Okubo, R., Hashimoto, M., Minoshima, K., & Wada, M. (2025). A case report on the long‐term use of teduglutide in a pediatric patient with short bowel syndrome. Nutrition in Clinical Practice. https://doi.org/10.1002/ncp.70023

Vancouver

Sakurai T, Kudo H, Megumi N, Ando R, Kazama T, Okubo R, et al. A case report on the long‐term use of teduglutide in a pediatric patient with short bowel syndrome. Nutrition in Clinical Practice. 2025. doi:10.1002/ncp.70023

BibTeX
@article{Sakurai2025,
  author = {Sakurai, Tsuyoshi and Kudo, Hironori and Megumi, Nakamura and Ando, Ryo and Kazama, Takuro and Okubo, Ryuji and Hashimoto, Masatoshi and Minoshima, Ko and Wada, Motoshi},
  title = {A case report on the long‐term use of teduglutide in a pediatric patient with short bowel syndrome},
  journal = {Nutrition in Clinical Practice},
  year = {2025},
  doi = {10.1002/ncp.70023}
}
Kostenlos starten →